Cosentyx snrdy 300MG dose-2PENML
Ended Awarded Last action
- Contract number
- SPE2DR26F5ZRC
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $61,880
Award facts
- Contract value 100% obligated
- $61,880.47 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $61,880.47 to AmerisourceBergen Drug Corp for the supply of Cosentyx (secukinumab) 300 mg dose in 2 mL pen format, with performance in Conshohocken, Pennsylvania and completion targeted for January 23, 2026. This competitively awarded, firm fixed-price contract contains no set-aside designation, reflecting the vendor's capability to compete on a full and open basis for federal pharmaceutical procurement requirements. The award represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, a $999,999,999 vehicle established through December 2026 that serves as the primary mechanism for delivering comprehensive pharmaceutical products and medical supplies to military healthcare programs globally.
AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor headquartered in Pennsylvania that specializes in supplying brand-name and generic medications, vaccines, and specialized medical commodities to federal agencies including the Defense Health Agency and U.S. Coast Guard. The Cosentyx delivery supports the military's medical supply chain requirements and demonstrates the contractor's role in providing critical prescription medications across multiple therapeutic domains to federal healthcare systems. The contract reflects DLA's ongoing strategy of utilizing prime vendor vehicles to ensure efficient, flexible access to essential pharmaceutical products for Department of Defense beneficiaries and military treatment facilities.
Quick answers
Who was awarded contract SPE2DR26F5ZRC?
SPE2DR26F5ZRC was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26F5ZRC worth?
The government has obligated $61,880 on SPE2DR26F5ZRC.
Is contract SPE2DR26F5ZRC an order under another contract?
Yes. SPE2DR26F5ZRC is a delivery order under SPE2DR25D2109, an indefinite delivery contract.
Was contract SPE2DR26F5ZRC competed?
The extent of competition for SPE2DR26F5ZRC was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award